We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

5 hedge funds and large institutions have $3.04K invested in NRX Pharmaceuticals Warrant in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding

Funds holding: 2 → 5 (+3)

0.02% more ownership

Funds ownership: 0.02% → 0.05% (+0.02%)

29% less capital invested

Capital invested by funds: $4.29K → $3.04K (-$1.25K)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$1.96K
2
UBS Group
UBS Group
Switzerland
+$1.23K
3
Bank of America
Bank of America
North Carolina
+$94

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
YCM
1
Yakira Capital Management
Connecticut
$1.37K – – –
WAM
2
Wolverine Asset Management
Illinois
$995 +$1.96K +12,426 New
UBS Group
3
UBS Group
Switzerland
$625 +$1.23K +7,812 New
Bank of America
4
Bank of America
North Carolina
$48 +$94 +600 New
TRCT
5
Tower Research Capital (TRC)
New York
$1 – – –

NRXPW Hedge Fund Activity: Q3 2023 in Review

5 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q3 2023, worth a combined $3.04K — down 29% from $4.29K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NRXPW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $1.96K.

  • 5 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q3 2023, up from 2 in Q2 2023.
  • Funds reported $3.04K of NRX Pharmaceuticals Warrant stock for Q3 2023, down 29% quarter-over-quarter.
  • 3 funds opened new NRX Pharmaceuticals Warrant positions in Q3 2023 and 0 closed out, a net change of +3 holders.
  • The largest NRX Pharmaceuticals Warrant buyer in Q3 2023 was Wolverine Asset Management, an estimated $1.96K added.

Based on aggregated 13F filings for Q3 2023.